# Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

> **NCT01329640** · PHASE2 · TERMINATED · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 9 (actual)

## Conditions studied

- Locally Advanced HER2-positive Breast Cancer

## Interventions

- **DEVICE:** Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide

## Key facts

- **NCT ID:** NCT01329640
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2011-09
- **Final completion:** 2012-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329640, "Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01329640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*